JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which ...

Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Vertex Pharmaceuticals (NASDAQ ... offering several treatments known as CFTR modulators. These products work by correcting a faulty protein that causes symptoms of the disease.

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new ... is expected to become a multi-billion dollar product if approved. It works by blocking pain signals at their origin before they ...

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corp. (TM) and Vertex Pharmaceuticals Inc ... driven by cost reductions and a ...

Vertex Pharmaceuticals Inc. will work with a Watertown ... milestones related to sickle cell disease and beta thalassemia products. Plus, Orna could get up to $365 million in additional option ...

Vertex Pharmaceuticals Inc. notched two FDA victories ... blockbuster CF drug, helping drive its product revenue to $9.87 billion last year. Alyftrek is approved for CF patients 6 years and ...